density

(redirected from bone mineral density)
Also found in: Dictionary, Thesaurus, Medical, Financial, Acronyms, Encyclopedia, Wikipedia.
References in periodicals archive ?
Analysis on correlation of serum levels of IGF-1 and ET-1 with cytokines and bone mineral density showed that serum levels of IGF-1 were in a significant negative correlation with levels of IL-18, IL-6 and hs-CRP, but in a significant positive correlation with bone mineral density; the serum level of ET-1 was in a significant positive correlation with levels of IL-18, IL-6 and hs-CRP, but in a significant negative correlation with bone mineral density (Table-IV).
In regression analyses, RF titers were independent risk factors for lower bone mineral density of the femoral neck.
This new study in middle-aged people with HIV is the largest and longest attempt to compare bone mineral density loss in women and men with HIV.1 The study also addresses the difficult question of how bone mineral density changes over time in HIV-positive people taking antiretroviral therapy for many years.
Table-III: Comparison of bone mineral density across various durations of low back pain.
Zamorano, "Comment on "Assessment of bone mineral density in male patients with chronic obstructive pulmonary disease by DXA and quantitative computed tomography"," International Journal of Endocrinology, vol.
The elderly women neither gained nor lost bone mineral density in the sample investigated.
This is supported by studies noting reduced bone mineral density (5), (6) and increased risk of fracture' with high-potential vs low- or no-potential antipsychotics.
Descriptive statistics for and Regression - stepwise multiple was used to predict bone mineral density via anthropometric variables in elderly women.
Researchers found that taking vitamin D supplements do not improve the bone mineral density in all adults.Bone mineral density is a measure of bone strength and measures the amount of bone mineral present at different sites in the body.
The Cockroft- Gault equation linked mild renal dysfunction with decreased bone mineral density.
Drug company Repros Therapeutics Inc (NasdaqCM:RPRX) said on Tuesday that it has provided interim six month results from the first 150 subjects enrolled into the ongoing one year placebo controlled study ZA-303 to assess the impact of Androxal treatment of secondary hypogonadal men and its effect on bone mineral density.